Integrative Oncology Therapy Research Association
Versione italiana
Subscribe Our Newsletter

Your Name (requested)

Your email (requested)

I accept the Privacy Policy

Watch Us on YouTube
Find Us On Facebook
External Links

Vatalanib (PTK 787/ZK 222584) GLEEVEC

Target and mechanism of action: this is a small molecule that binds to tyrosine kinase of receptors VEGF and platelet growth factor (platelet-derived growth factor or PDGF) blocking the function and consequently inhibit the formation of new blood vessels in the tumor.

Indications: the drug is corrently being studied in cancers of the colon and rectum, in combination with chemotherapy.

Mode of administration: it is administered orally as tablets.

Most common side effects: asthenia, diarrhea, nausea, dizziness, headache, hypertension.

Trade name: it is currently still under study and is not marketed in any country (pharmaceutical companies Novartis and Schering AG).

Leave a Reply

Your email address will not be published. Required fields are marked *